Publications

This report provides information about our regulatory performance for the 2023-24 financial year.

Detailed statistical information on Therapeutic Goods Administration performance in pre- and post-market activities.

This report provides an overview of pharmacovigilance inspection deficiencies in 2022, including a comparison to results from previous reporting periods.

The findings will inform the need for any risk management actions to ensure public safety.

This plan outlines our compliance and education priorities for 2024-2025.

Read our 2024 stakeholder survey report, which aims to improve the way we work with our stakeholders.

We commissioned the Health Design Lab to conduct market research to better understand the individual consumer, pharmacist and prescriber experiences of shortages and discontinuations.

Read our business plan 2024-25 to find out about our strategic priorities and activities.

Find out how we are managing shortages of medicines and taking action to limit their effects. Read our 2024 report.

Documents released under the FOI Act in the 2023/24 financial year